China Children’s Drug R&D and Industrialization Alliance
Children’s health is related to the future of the country and the nation. In recent years, the party and the state have made many fruitful efforts to continuously improve the health of children and further improve the medication security system. However, problems such as lack of special medicines for children, insufficient suitable medicines, and incomplete information on medication still need to be solved urgently. The integrated development of drug administration, production, academia, research, use and financing promotes the research and development and industrialization of children’s drugs.
In order to give full play to the “medicine-industry collaboration” and “science-health collaboration” mechanisms and to more closely integrate R&D, production and clinical needs,In 2020, with the joint support of the National Health Commission, the Ministry of Industry and Information Technology, and the Food and Drug Administration, 23 institutions including pharmaceutical companies, scientific research institutes, and clinical institutions will jointly initiate the establishment of “China Children’s Drugs” R&D and Industrialization Alliance” (hereinafter referred to as Pediatric Drug Alliance). The alliance aims to promote the linkage of “government-industry-university-research-medical-funding”, explore the establishment of children’s drug research and development and industrialization including research and development and transformation, technical support system, and talent training Platform to improve the research and development capabilities, transformation efficiency and innovation level of children’s medicines in my country, and lead the sustainable, rapid and healthy development of children’s medicines.
The Pediatric Medicine Alliance has started the recruitment of the second batch of member units, and sincerely invites outstanding industry colleagues to participate and work together to jointly promote the promotion of children’s medicine in my country Efficient, high-quality, innovative development and work hard!
Pediatric Medicine Alliance members accept the new standard
Basic StandardMain Unit
Institutes, universities, medical institutions It must be a first-level unit of the institution, and the pharmaceutical enterprise is the parent company of the group.
social reputation
The applicant has a good social reputation.
Social Responsibility
Actively practice social responsibility; make outstanding contributions to promoting the development of pediatric medicine.
Responsibilities and Obligations
1. Support and abide by the regulations of China Children’s Drug Research and Development and Industrialization Alliance;
2. Actively undertake the responsibilities and obligations of the Alliance members;
3. Actively participate in the activities of the Pediatric Drug Alliance, and Suggestions and suggestions for the development of the alliance.
Registration type
The company is registered in mainland China Pharmaceutical companies; Listed companies are excellentFirst.
Enterprise scale
The annual top 200 pharmaceutical industry enterprises in the “China Pharmaceutical Statistics Annual Report” of the Ministry of Industry and Information Technology.
Pediatrics product line
1 . More than 1/5 of the main business income of the company’s pharmaceuticals is pediatric drugs;
2. At least one major pediatric drug has sales (tax included) in the market: chemical drugs Not less than 300 million yuan, and Chinese patent medicines not less than 100 million yuan or more.
R&D strength
p>
1. Possess mature children’s drug research and development capabilities and achievement transformation capabilities;
2. The company has continuous innovation capabilities and has obtained no less than 2 items Invention patents related to major children’s drug products;
3. Presided over (participated in) the formulation (revision) of national standards, industry standards, group standards, etc. in related business fields, which can be given priority .
II.Clinical institutions
Institution type
National leading tertiary first-class pediatric hospital (such as the National Children’s Regional Medical Center may be preferred) or with high-level pediatric clinical General hospital with diagnosis and treatment capabilities.
Research strength
1. Have undertaken national-level pediatric-related scientific research projects within five years, and outstanding achievements are preferred;< /p>
2. Those with “pediatric characteristic medical institution preparations” are preferred.
Third, colleges and universities
0
University institutes
The Ministry of Education “double first-class” construction universities; related professional disciplines.
Research Scope
Engaged in the research of policies, industries and drugs of China’s pharmaceutical and health industry.
Research strength
1. Have well-known experts, scholars or research groups related to children’s medicine, and have high-level scientific research
2. undertakesnational-level pediatric-relatedresearch projects within five years, Those who have outstanding achievements are preferred;
3. Successful cases are preferred.
[The final interpretation right belongs to the China Children’s Drug R&D and Industrialization Alliance]
Please scan the code to fill in the basic application materialsstrong text END
strong recommended /span>
heightcontent =”300″ layout=”responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_jpg/AnRWiconRdaf9xjXVbf44ur10jfquZKbzPtHkZxBKfMLialUTLF9SOQFfxibXUetvPBMmbAy5ZtrxL289vLZIj0wg/640″ width=”600″>
For more data insight information or public account content cooperation, please contact Medical Geography Assistant WeChat ID: pharmadl001
share< >Favorites LikeWatching
small Only children make choices, I want to be an adult